Market Place
Sourcing Support
Y-mAbs Presents Neuroblastoma Research At AACR Pediatric Cancer Conference
06 Sep 2024 //
GLOBENEWSWIRE
Y-mAbs to Participate in Upcoming Investor Conferences in September
03 Sep 2024 //
GLOBENEWSWIRE
Y-mAbs` Naxitamab Shows New Phase 2 Interim Analysis At ASCO 2024
01 Jun 2024 //
GLOBENEWSWIRE
Y-mAbs Q1 2024 Results and Recent Developments
07 May 2024 //
GLOBENEWSWIRE
Y-mAbs Therapeutics Naxitamab-gqgk Receives Suppl Approval in the U.S
20 Mar 2024 //
FDA
Y-mAbs DANYELZA for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 May 2023 //
GLOBENEWSWIRE
Y-mAbs Reports 1Q 2023 FYR and Recent Corporate Developments and Updates 2023
08 May 2023 //
GLOBENEWSWIRE
Y-mAbs and EMA Reach Agreement on the Pediatric Investigation Plan for Naxitamab
02 Feb 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA
21 Dec 2022 //
GLOBENEWSWIRE
Y-mAbs’ DANYELZA® for the Treatment of High-Risk Neuroblastoma Approved in China
08 Dec 2022 //
GLOBENEWSWIRE
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
26 Sep 2022 //
GLOBENEWSWIRE
Y-mAbs`s Naxitamab Chemoimmunotherapy Trial Meets Primary Endpoint
26 May 2022 //
GLOBENEWSWIRE
Y-mAbs to Host Webinar on DANYELZA Frontline and HITS Data in Neuroblastoma
10 Sep 2021 //
GLOBENEWSWIRE
With pipeline setbacks mounting, United snares priority voucher formulation
29 Dec 2020 //
ENDPTS
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA®
18 Dec 2020 //
GLOBENEWSWIRE
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk)
18 Dec 2020 //
GLOBENEWSWIRE
Y-mAbs Takeda Announce Exclusive License and Distribution Agreement
04 Dec 2020 //
STREETINSIDER
FDA grants accelerated approval to naxitamab for high-risk neuroblastoma
30 Nov 2020 //
FDA
FDA Approves Naxitamab for Treatment of Relapsed High-Risk Neuroblastoma
27 Nov 2020 //
TARGETEDONC
Y-mAbs Danyelza (Naxitamab-gqgk) Receives Supplemental Approval In US
26 Nov 2020 //
FDA
Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma
16 Oct 2020 //
GLOBENEWSWIRE
Y-mAbs Announces USFDA Acceptance of Biologics License Application for Danyelza
01 Jun 2020 //
GLOBENEWSWIRE
Y-mAbs` naxitamab shows positive effect in neuroblastoma study
25 Oct 2019 //
SEEKINGALPHA
Y-mAbs ramps up head count in post-IPO hiring spree
15 Aug 2019 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.